Cargando…

LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma

BACKGROUND: Immunotherapy is a standard-of-care first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). However, many patients will develop resistance to first-line therapy, and effective second- and later-line treatment options are therefore needed. The von Hippel-Lindau (VHL) ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDermott, David F, Peer, Avivit, Agarwal, Neeraj, Atkins, Michael B, Cornell, Jerry, Perini, Rodolfo F, Grossmann, Kenneth F, Gurney, Howard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Trials in Progress Abstract Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445559/ http://dx.doi.org/10.1093/oncolo/oyad216.017

Ejemplares similares

SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY
por: Narayan, Vivek, et al.
Publicado: (2023)

Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling
por: Marathe, Dhananjay D., et al.
Publicado: (2023)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL
por: Arevalo, Aileen, et al.
Publicado: (2022)

A single institution experience with palbociclib toxicity requiring dose modifications
por: Gong, Jun, et al.
Publicado: (2017)

First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
por: Dhawan, Andrew, et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
por: Riedel, Richard F., et al.
Publicado: (2020)

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
por: Wilson, Florence R., et al.
Publicado: (2017)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
por: Rugo, H. S., et al.
Publicado: (2019)

Study protocol: A comparison of mobile and clinic‐based spirometry for capturing the treatment effect in moderate asthma
por: Izmailova, Elena S., et al.
Publicado: (2023)

Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
por: Finn, Richard S., et al.
Publicado: (2020)

Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
por: Sorah, Jonathan D, et al.
Publicado: (2022)

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
por: Finn, Richard S., et al.
Publicado: (2020)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

P03-024 – Early onset IBD treated by tocilizumab
por: Helbling, R, et al.
Publicado: (2013)

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
por: Albanell, Joan, et al.
Publicado: (2023)

Letrozole in the neoadjuvant setting: the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

S-Adenosyl-Methionine and Betaine Improve Early Virological Response in Chronic Hepatitis C Patients with Previous Nonresponse
por: Filipowicz, Magdalena, et al.
Publicado: (2010)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
por: Qu, Fei-Lin, et al.
Publicado: (2022)

PW03-024 - A transgenic mouse model for variant procaspase-1
por: Hermsdorf, A, et al.
Publicado: (2013)

CMS ARDA Meeting, ARDA-Note-2004-024
por: CERN. Geneva
Publicado: (2004)

Overall Survival with Palbociclib and Fulvestrant in Women with HR(+)/HER2(−) ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
por: Cristofanilli, Massimo, et al.
Publicado: (2022)

PW02-024-B - First report of AA amyloidosis in Blau syndrome
por: Ruiz-Ortiz, E, et al.
Publicado: (2013)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

PD-1 as a potential target in cancer therapy
por: McDermott, David F, et al.
Publicado: (2013)

P02-024 - Clinical impact of V198M mutation in NLRP3 gene
por: Caorsi, R, et al.
Publicado: (2013)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer
por: Davey, Matthew G., et al.
Publicado: (2023)

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
por: Turner, Nicholas C., et al.
Publicado: (2019)

EPCT-05. A PHASE I TRIAL OF THE CDK 4/6 INHIBITOR PALBOCICLIB IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR REFRACTORY CNS TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
por: Van Mater, David, et al.
Publicado: (2020)

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
por: Regan, Meredith M., et al.
Publicado: (2021)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
por: Elliott, Daisy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hd22svu1mun9vvpku62u9pfjag